Geneoscopy, Inc. has raised $105 million in Series C funding, led by Bio-Rad Laboratories, to support the launch of ColoSense®, a non-invasive stool-based colorectal cancer screening test. The funding will also drive innovation in diagnostic tools for inflammatory bowel disease (IBD). ColoSense leverages Geneoscopy’s proprietary RNA technology and Bio-Rad’s Droplet Digital PCR (ddPCR™) platform, offering highly sensitive and specific cancer detection.
Key Points:
- ColoSense Launch: Geneoscopy aims to commercialize its FDA-approved ColoSense test, addressing barriers to colorectal cancer screening for individuals aged 45 and older.
- Improved Access and Cost Savings: The non-invasive test could enhance early cancer detection and reduce healthcare costs compared to invasive procedures like colonoscopies.
- Strategic Collaborations: Partnerships with Labcorp and others aim to expand ColoSense’s accessibility and integrate it into comprehensive screening programs.
- Innovative Pipeline: The funding will also support new diagnostic solutions for IBD, addressing critical unmet medical needs.
- Bio-Rad’s Role: Bio-Rad emphasizes the transformative potential of combining ColoSense with its ddPCR platform to advance clinical diagnostics in oncology.